TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.
High serum levels of soluble TRAIL (sTRAIL) before or during the first year of Interferon-beta (IFN-beta) therapy were shown to predict an individual therapeutic response of patients with relapsing-remitting multiple sclerosis (RRMS). Here, we investigated whether sTRAIL plasma levels during long-term IFN-beta treatment correlate with future therapeutic response or adverse effects of treatment. Postinjection short-time bursts of sTRAIL were associated with flu-like symptoms and IP-10/CXCL10 as well as MCP-1/CCL2 induction, and were detected after up to 6 years of continuous IFN-beta therapy. However, neither sTRAIL nor chemokine levels allowed prediction of one- and two-year clinical treatment response in 30 RRMS patients, prospectively followed by blinded investigators.
Buttmann
Mathias
M
Department of Neurology, Julius-Maximilians-University, Josef-Schneider-Strasse 11, Würzburg, Germany. m.buttmann@uni-wuerzburg.de
Merzyn
Cornelia
C
Hofstetter
Harald H
HH
Rieckmann
Peter
P
D000328:Adult; D015415:Biomarkers / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood* / Q000187:drug effects / Q000276:immunology; D054357:Chemokine CXCL10 / Q000097:blood* / Q000187:drug effects / Q000276:immunology; D005260:Female; D006801:Humans; D007251:Influenza, Human / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D016899:Interferon-beta / Q000009:adverse effects* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood* / Q000187:drug effects / Q000276:immunology
D015415:Biomarkers; C111835:CCL2 protein, human; C114753:CXCL10 protein, human; D018932:Chemokine CCL2; D054357:Chemokine CXCL10; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D016899:Interferon-beta